Evidence map›Paper›PMID 39436937›Full record

ArticlePloS one2024

From colon wall to tumor niche: Unraveling the microbiome's role in colorectal cancer progression.

Gissel García Menéndez, Liubov Sichel, Maria Del Consuelo López, Yasel Hernández, Ernesto Arteaga, Marisol Rodríguez, Vilma Fleites, Lipsy Teresa Fernández, Raúl De Jesus Cano

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Integrated Gut Microbiome and Metabolome Analysis in Largemouth Bass (Animals : an open access journal from MDPI · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Embryonic Signaling Pathways Shape Colorectal Cancer Subtypes: Linking Gut Development to Tumor Biology.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  11. Effect of Raspberry (Foods (Basel, Switzerland) · 2025
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gissel García MenéndezPathology Department, Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.ORCID 0000-0002-9851-2041
Liubov SichelStellar Biotics, LLC, Rockleigh, New Jersey, United States of America.
Maria Del Consuelo LópezPathology Department, Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Yasel HernándezPathology Department, Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Ernesto ArteagaPathology Department, Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Marisol RodríguezPathology Department, Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Vilma FleitesOncology Department Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Lipsy Teresa FernándezSurgery Department Clinical Hospital Hermanos Ameijeiras, Centro Habana, La Habana, Cuba.
Raúl De Jesus CanoBiological Sciences Department, California Polytechnic State University, San Luis Obispo, CA, United States of America.ORCID 0000-0001-6888-5018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is influenced by perturbations in the colonic microbiota, characterized by an imbalance favoring pathogenic bacteria over beneficial ones. This dysbiosis contributes to CRC initiation and progression through mechanisms such as carcinogenic metabolite production, inflammation induction, DNA damage, and oncogenic signaling activation. Understanding the role of external factors in shaping the colonic microbiota is crucial for mitigating CRC progression. This study aims to elucidate the gut microbiome's role in CRC progression by analyzing paired tumor and mucosal tissue samples obtained from the colon walls of 17 patients. Through sequencing of the V3-V4 region of the 16S rRNA gene, we characterized the tumor microbiome and assessed its association with clinical variables. Our findings revealed a significant reduction in alpha diversity within tumor samples compared to paired colon biopsy samples, indicating a less diverse microbial environment within the tumor microenvironment. While both tissues exhibited dominance of similar bacterial phyla, their relative abundances varied, suggesting potential colon-specific effects. Fusobacteriota enrichment, notably in the right colon, may be linked to MLH1 deficiency. Taxonomy analysis identified diverse bacterial genera, with some primarily associated with the colon wall and others unique to this region. Conversely, several genera were exclusively expressed in tumor tissue. Functional biomarker analysis identified three key genes with differential abundance between tumor microenvironment and colon tissue, indicating distinct metabolic activities. Functional biomarker analysis revealed three key genes with differential abundance: K11076 (putrescine transport system) and K10535 (nitrification) were enriched in the tumor microenvironment, while K11329 (SasA-RpaAB circadian timing mediator) dominated colon tissue. Metabolic pathway analysis linked seven metabolic pathways to the microbiome. Collectively, these findings highlight significant gut microbiome alterations in CRC and strongly suggest that long-term dysbiosis profoundly impacts CRC progression.

Indexed as

ColonColorectal NeoplasmsDisease ProgressionGastrointestinal MicrobiomeAgedBacteriaFemaleHumansMaleMiddle AgedRNA, Ribosomal, 16STumor MicroenvironmentRNA, Ribosomal, 16S

Identifiers

PMID39436937
PMCPMC11495602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.